www.agadabio.com

Facilitating orphan drug development

AGADA BioSciences is a clinical research organization (CRO) housed within the Innovacorp Enterprise Center on Summer St on the Dalhousie University campus.

AGADA provides pre-clinical and clinical research and services to an international clientele of pharmaceutical and biotechnology companies, as well as stake holder foundations.

AGADA was initiated through a spin-off of a highly successful pre-clinical efficacy core facility at Children’s National Medical Center in Washington DC, designed and managed by Kanneboyina Nagaraju DVM PhD and Eric Hoffman PhD.

Founded in 2013, AGADA employs a dozen highly educated and motivated staff to carry out drug trials in mouse models of human disease.  Positive results typically become an important aspect of a company’s orphan drug application to the FDA or EMA, and a proof of principle of drug mechanism of action and therapeutic benefit.

In the 3rd year of operation, AGADA generated revenues of $2.3M, and shows a double digit annual growth rate.

AGADA is expanding services to support pharmacodynamic biomarker discovery and integration into both pre-clinical and clinical programs.  AGADA works closely with Dalhousie University, helping facilitate their growing rare disease and orphan drug development programs.

AGADA Biosciences Inc.
1344 Summer St., Suite 312
Halifax, Nova Scotia
B3H 0A8

Contact Information:

Amanda Mullen, Senior Manager of Operations
Phone: (902) 442-4011
Email: AMullen@agadabio.com

 

AGADA Brochure 2016
thumbnail of 2016-agada-brochure